Previous 10 | Next 10 |
3 Top Penny Stocks to Add to Your Watchlist Right Now When it comes to buying penny stocks, knowing what is going on in the stock market is crucial. This means having a thorough understanding of the latest market news and events. While there are a number of ways to get this information,...
The stock market is down again today. Why? Concerns stemming from last week’s Fed meeting and plenty of Fed speak this week have contributed to the latest stock market rout. But that hasn’t been the same when it comes to penny stocks. In this article, we look at a hand full of...
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Source: Shutterstock.com Lava Therapeutics (NASDAQ: LVTX ) stock is rocketing higher on Monday as investors react to news of an exclusive global license agreement with Seagen (NASDAQ: SGEN ). This agree...
– Seagen to Develop and Commercialize LAVA-1223, a Bispecific T Cell Engager Designed to Target and Activate Vγ9Vδ2 ( Gamma Delta) T Cells in the Presence of EGFR-Expressing Solid Tumors – – LAVA to Receive Upfront Payment of $50 Million,...
LAVA Therapeutics press release ( NASDAQ: LVTX ): Q2 GAAP EPS of -$0.31 beats by $0.30 . Revenue of $0.47M (-56.5% Y/Y) beats by $0.11M . As of June 30, 2022, LAVA had cash, cash equivalents, and investments totaling $110.7 million compared to cash and cash equ...
Initial Phase 1/2a clinical findings for LAVA-051 in patients with chronic lymphocytic leukemia and multiple myeloma patients demonstrated encouraging anti-tumor activity and safety profile; on track to report additional clinical data in fourth quarter 2022 Enrollment cont...
UTRECHT, The Netherlands and PHILADELPHIA, Sept. 07, 2022 (GLOBE NEWSWIRE) -- LAVA Therapeutics N.V. ( Nasdaq: LVTX ), a clinical stage immuno-oncology company focused on developing its proprietary Gammabody™ platform of bispecific gamma delta T cell engagers to transform the...
UTRECHT, The Netherlands and PHILADELPHIA, June 16, 2022 (GLOBE NEWSWIRE) -- LAVA Therapeutics N.V. ( Nasdaq: LVTX ), a clinical stage immuno-oncology company focused on developing its proprietary Gammabody™ platform of bispecific gamma delta T cell engagers to transform the ...
UTRECHT, The Netherlands and PHILADELPHIA, June 15, 2022 (GLOBE NEWSWIRE) -- LAVA Therapeutics N.V. ( Nasdaq: LVTX ), a clinical stage immuno-oncology company focused on developing its proprietary Gammabody™ platform of bispecific gamma delta T cell engagers to transform the ...
UTRECHT, The Netherlands and PHILADELPHIA, June 02, 2022 (GLOBE NEWSWIRE) -- LAVA Therapeutics N.V. ( Nasdaq: LVTX ), a clinical stage immuno-oncology company focused on developing its proprietary Gammabody™ platform of bispecific gamma delta T cell engagers to transform the ...
News, Short Squeeze, Breakout and More Instantly...
LAVA Therapeutics N.V. Company Name:
LVTX Stock Symbol:
NASDAQ Market:
LAVA Therapeutics N.V. Website:
UTRECHT, The Netherlands and PHILADELPHIA, June 20, 2024 (GLOBE NEWSWIRE) -- LAVA Therapeutics N.V. (NASDAQ: LVTX, “LAVA”), a clinical-stage immuno-oncology company focused on developing its proprietary Gammabody ® platform of bispecific gamma delta T cell eng...
UTRECHT, The Netherlands and PHILADELPHIA, May 30, 2024 (GLOBE NEWSWIRE) -- LAVA Therapeutics N.V. (NASDAQ: LVTX, “LAVA,” or “Company”), a clinical-stage immuno-oncology company focused on developing its proprietary Gammabody® platform of bispecific gamm...
LAVA-1207 dose escalation progressing in Phase 1/2a trial in prostate cancer, with pembrolizumab combination expected to begin in Q2 2024 Received $7.0 million clinical development milestone from Pfizer for PF-08046052 (formerly LAVA-1223) in Phase 1 LAVA-1266 on track for Q2 2024 IND sub...